Importance

Loading Importance Indicators...

Abstract

This disclosure is concerned with Anaerobutyricum soehngenii or relative thereof for use in preventing and/or treating hepatic steatosis, particularly nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH), wherein the use is for increasing bile acid plasma level for reducing liver inflammation and/or for reducing hepatic necroinflammatory activity score. The Anaerobutyricum soehngenii or relative thereof may be combined with at least one Bifidobacterium species, preferably Bifidobacterium animalis subspecies lactis or relative thereof and/or Bifidobacterium breve or relative thereof. In addition or alternatively, the Anaerobutyricum soehngenii or relative thereof may be combined with at least one Akkermansia species, preferably Akkermansia muciniphila or relative thereof. In addition or alternatively, the Anaerobutyricum soehngenii or relative thereof may be combined with at least one Lactobacillus species, preferably Lactobacillus acidophilus or relative thereof, Lactobacillus casei or relative thereof and/or Lactobacillus reuteri or relative thereof.

Loading the Abstract Image...

First Claim